×

Endologix to Participate in Two Investor Conferences in May

IRVINE, Calif., April 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first conference is the Deutsche Bank 41st Annual Health Care Conference in Boston, Massachusetts.

Event:Deutsche Bank 41st Annual Health Care Conference
Date:Thursday May 5, 2016
Time:11:20 am ET
Participant:Vaseem Mahboob, Chief Financial Officer

The second conference is the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada.

Event:Bank of America Merrill Lynch 2016 Health Care Conference
Date:Tuesday May 10, 2016
Time:6:40 pm ET / 3:40 pm PT
Participants:John McDermott, Chief Executive Officer
Vaseem Mahboob, Chief Financial Officer

An audio webcast of the Company’s presentations at these conferences will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.


COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020

Source:Endologix